High concentration VEGF receptor fusion protein containing formulations
Patent Information
- Application Number
- HK42026125695
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2019-03-05
- Filing Date
- 2026-07-03
- Publication Date
- 2026-09-18
- Estimated Expiration
- 2039-05-09
Smart Images
Figure 00000001_0000 
Figure 00000001_0001 
Figure 00000002_0000
Abstract
Description
Abstract This invention provides an ophthalmic formulation having a high concentration of vascular endothelial growth factor (VEGF) receptor fusion protein and exhibiting high stability during storage. A method for treating vascular eye diseases using this high-concentration formulation is also provided. Figure 1A Figure 1B Figure 1C Figure 1D
Claims
1. Aflibercept for use in the treatment of an angiogenic eye disorder in a subject in need thereof, said treatment comprising administering an intravitreal injection of about 8 mg of said aflibercept to an eye of the subject.
2. Aflibercept for the use according to claim 1, wherein the aflibercept is administered in an injection volume of about 50 microliters, about 60 microliters, about 70 microliters, or about 75 microliters.
3. Aflibercept for the use according to claim 1 or 2, wherein the angiogenic eye disorder is age-related macular degeneration (wet), macular edema, macular edema following retinal vein occlusion, retinal vein occlusion (RVO), central retinal vein occlusion (CRVO) branch retinal vein occlusion (BRVO), diabetic macular edema (DME), choroidal neovascularization (CNV), iris neovascularization, neovascular glaucoma, post-surgical fibrosis in glaucoma, proliferative vitreoretinopathy (PVR), optic disc neovascularization, corneal neovascularization, retinal neovascularization, vitreal neovascularization, pannus, pterygium, vascular retinopathy, diabetic retinopathy, non-proliferative diabetic retinopathy and / or proliferative diabetic retinopathy.